前列腺癌治疗市场规模、份额和成长分析（按药物类型、分销管道和地区）- 产业预测 2025-2032

2023 年摄护腺癌治疗市场规模价值 121 亿美元，预计将从 2024 年的 130.6 亿美元成长到 2032 年的 239.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.9%。

全球市场格局正在经历充满活力且不断发展的转变，主要原因是人口老化、意识提高和早期诊断导致男性前列腺癌发病率不断上升。发病率的快速增加刺激了创新治疗方法的发展。然而，高昂的治疗费用和潜在的副作用等问题可能会阻碍其更广泛地应用。关键成长要素包括药物选择的增加、大量的研发投入、复杂的药物管道的引入、以及非转移性去势抗性和转移性荷尔蒙非依赖性疾病的荷尔蒙疗法的扩展。新兴经济体中尚未开发的商业机会可能会进一步推动这个市场的发展，儘管在恢復时间和需求方面会受到一些限制。个人化治疗策略和增强药物针对性的转变可能会推动未来的进步并显着改善患者的治疗效果。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

前列腺癌治疗市场规模（按药物类型和复合年增长率） (2025-2032)

• 市场概况
• 用荷尔蒙疗法治疗前列腺癌
  • 黄体激素释放激素 (LHRH) 拮抗剂
  • 泽泻
  • 戈纳克斯
  • 黄体激素释放激素 (LHRH)促效剂
  • 亮丙瑞林
  • Zoladex
  • 艾利加德
  • 十甲哌啶
  • 万塔斯
  • 其他的
  • 抗雄激素
  • 赞迪
  • 卡索得
• 摄护腺癌化疗
  • Taxotere
  • 杰夫塔纳
• 摄护腺癌免疫治疗
  • Provenge
• 标靶治疗
  • 佐菲戈
• 其他前列腺癌

前列腺癌治疗市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 药局和药房
• 网路药局

前列腺癌治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• GSK Plc（UK）
• Merck KGaA（Germany）
• Viatris Inc.（USA）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Exelixis Inc.（USA）
• IBSA Pharma（IBSA Group）（Switzerland）
• Abbott Laboratories（USA）
• Alvogen Iceland ehf（Iceland）
• Fresenius SE & Co. KGaA（Germany）
• Jerome Stevens Pharmaceuticals Inc.（USA）
• Lannett Co. Inc.（USA）
• Lupin Ltd.（India）
• Mayne Pharma Group Ltd.（Australia）
• Piramal Enterprises Ltd.（India）
• RLC Labs Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）

结论和建议

Prostate Cancer Treatment Market size was valued at USD 12.1 billion in 2023 and is poised to grow from USD 13.06 billion in 2024 to USD 23.99 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).

The global prostate cancer treatment market presents a vibrant and evolving landscape, primarily driven by the increasing prevalence of prostate cancer among men due to an aging population, heightened awareness, and early diagnosis. This surge in incidence fosters the development of innovative treatments. However, challenges such as high treatment costs and potential side effects may hinder broader adoption. Key growth factors include the rise in pharmaceutical options, significant R&D investments, the introduction of complex pipeline drugs, and the expansion of hormonal therapies in both non-metastatic castration-resistant and metastatic hormone-naive conditions. Untapped opportunities in developing economies could further propel this market, albeit with some limitations in healing periods and demand. A shift toward personalized treatment strategies and enhanced drug targeting will likely drive future advancements, improving patient outcomes significantly.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Treatment Market Segments Analysis

Global Prostate Cancer Treatment Market is segmented by Drug Type, Distribution Channel and region. Based on Drug Type, the market is segmented into Hormonal Prostate Cancer Therapy, Prostate Cancer Chemotherapy, Prostate Cancer Immunotherapy, Prostate Cancer Targeted Therapy and Others Prostate Cancer. Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Prostate Cancer Treatment Market

The Prostate Cancer Treatment market is primarily driven by the rising prevalence of prostate cancer, which is influenced by various factors such as an aging global population and advancements in awareness and diagnostic techniques. As the population ages, it is expected that prostate cancer incidence will rise significantly, particularly since the disease predominantly affects older men. Enhanced awareness and widespread screening initiatives have contributed to the earlier detection of prostate cancer, leading to increased reported cases. These elements highlight the pressing need for effective treatment options and foster the development of innovative therapies within this dynamic market.

Restraints in the Prostate Cancer Treatment Market

The global market for prostate cancer treatment encounters notable obstacles, primarily due to the substantial costs linked to targeted therapies and immunotherapies. While these advanced treatment options have demonstrated significant potential for enhancing patient outcomes, their affordability poses a serious challenge. The expenses associated with therapies like immunosuppressants can be exceedingly high, imposing a considerable financial strain on both patients and healthcare systems. This elevated cost frequently restricts access to these crucial therapies, hindering the ability to provide effective care. A limited number of patients worldwide face the difficult task of managing the financial implications, highlighting the urgent need to address cost-related barriers to ensure wider access to these potentially life-saving treatments.

Market Trends of the Prostate Cancer Treatment Market

The prostate cancer treatment market is increasingly trending towards personalized medicine, highlighting a shift towards tailored therapeutic strategies based on individual genetic and molecular profiles. Advances in genomic testing allow for the identification of specific biomarkers, enabling healthcare providers to select the most effective treatment options while minimizing unnecessary interventions and side effects. Technologies such as the Prostate Health Index and genomic tests like Oncotype DX are at the forefront of this transformation. Furthermore, targeted therapies like olaparib and rucaparib are becoming critical in treating advanced cases by addressing DNA repair pathway alterations, enhancing the overall efficacy of prostate cancer management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Prostate Cancer Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Hormonal Prostate Cancer Therapy
  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
  • Zytiga
  • Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
  • Lupron
  • Zoladex
  • Eligard
  • Decapeptyl
  • Vantas
  • Others
  • Anti-Androgen
  • Xtandi
  • Casodex
• Prostate Cancer Chemotherapy
  • Taxotere
  • Jevtana
• Prostate Cancer Immunotherapy
  • Provenge
• Prostate Cancer Targeted Therapy
  • Xofigo
• Others Prostate Cancer

Global Prostate Cancer Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Prostate Cancer Treatment Market Size & CAGR (2025-2032)

• North America (Drug Type, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBSA Pharma (IBSA Group) (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvogen Iceland ehf (Iceland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jerome Stevens Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RLC Labs Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations